For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
Conmed Corp (NYSE: CNMD) closed the day trading at $40.57 up 1.25% from the previous closing price of $40.07. In other words, the price has increased by $1.25 from its previous closing price. On the day, 0.91 million shares were traded. CNMD stock price reached its highest trading level at $41.31 during the session, while it also had its lowest trading level at $39.8066.
Ratios:
For a better understanding of CNMD, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 32.27 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.43. For the most recent quarter (mrq), Quick Ratio is recorded 0.95 and its Current Ratio is at 2.10. In the meantime, Its Debt-to-Equity ratio is 0.85 whereas as Long-Term Debt/Eq ratio is at 0.85.
On April 28, 2025, Stifel Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $55.
JP Morgan Downgraded its Overweight to Neutral on February 06, 2025, whereas the target price for the stock was revised from $85 to $70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 21 ’25 when Glaze Richard sold 257 shares for $41.21 per share. The transaction valued at 10,591 led to the insider holds 0 shares of the business.
Glaze Richard bought 257 shares of CNMD for $10,591 on Nov 21 ’25. On Nov 06 ’25, another insider, Garner Todd W, who serves as the Executive Vice President & CFO of the company, sold 3,500 shares for $43.00 each. As a result, the insider received 150,500 and left with 1,836 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNMD now has a Market Capitalization of 1256369920 and an Enterprise Value of 2055709952. As of this moment, Conmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.70, and their Forward P/E ratio for the next fiscal year is 8.94. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.71. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.93 while its Price-to-Book (P/B) ratio in mrq is 1.25. Its current Enterprise Value per Revenue stands at 1.526 whereas that against EBITDA is 9.102.
Stock Price History:
The Beta on a monthly basis for CNMD is 0.96, which has changed by -0.46387476 over the last 52 weeks, in comparison to a change of 0.13844287 over the same period for the S&P500. Over the past 52 weeks, CNMD has reached a high of $76.34, while it has fallen to a 52-week low of $38.95. The 50-Day Moving Average of the stock is -9.22%, while the 200-Day Moving Average is calculated to be -22.15%.
Shares Statistics:
Over the past 3-months, CNMD traded about 449.64K shares per day on average, while over the past 10 days, CNMD traded about 620630 shares per day. A total of 30.96M shares are outstanding, with a floating share count of 30.02M. Insiders hold about 3.05% of the company’s shares, while institutions hold 109.70% stake in the company. Shares short for CNMD as of 1763078400 were 2249552 with a Short Ratio of 5.00, compared to 1760486400 on 2097899. Therefore, it implies a Short% of Shares Outstanding of 2249552 and a Short% of Float of 9.92.
Dividends & Splits
CNMD’s forward annual dividend rate is 0.80, up from 0.8 a year ago. Against a Trailing Annual Dividend Yield of 0.019965062. The stock’s 5-year Average Dividend Yield is 0.93. The current Payout Ratio is 18.82% for CNMD, which recently paid a dividend on 2025-09-15 with an ex-dividend date of 2025-09-15. Stock splits for the company last occurred on 2001-09-10 when the company split stock in a 3:2 ratio.
Earnings Estimates
The stock of Conmed Corp (CNMD) is currently being evaluated by 6.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0.95, with high estimates of $1.0 and low estimates of $0.91.
Analysts are recommending an EPS of between $4.51 and $4.48 for the fiscal current year, implying an average EPS of $4.5. EPS for the following year is $4.54, with 6.0 analysts recommending between $4.95 and $4.15.
Revenue Estimates
6 analysts predict $366.88M in revenue for. The current quarter. It ranges from a high estimate of $368.5M to a low estimate of $365.94M. As of. The current estimate, Conmed Corp’s year-ago sales were $345.94MFor the next quarter, 6 analysts are estimating revenue of $330.02M. There is a high estimate of $342.35M for the next quarter, whereas the lowest estimate is $317.68M.
A total of 6 analysts have provided revenue estimates for CNMD’s current fiscal year. The highest revenue estimate was $1.37B, while the lowest revenue estimate was $1.37B, resulting in an average revenue estimate of $1.37B. In the same quarter a year ago, actual revenue was $1.31BBased on 6 analysts’ estimates, the company’s revenue will be $1.39B in the next fiscal year. The high estimate is $1.44B and the low estimate is $1.34B.
